<DOC>
	<DOCNO>NCT01091207</DOCNO>
	<brief_summary>With discovery KIT ( CD117 ) mutation advent KIT tyrosine kinase inhibitor imatinib , substantial improvement overall survival patient advance and/or metastatic gastrointestinal tumor ( GIST ) . Recently , sunitinib show activity second-line therapy GIST patient failure imatinib . However , virtually patient eventually progress become intolerable imatinib sunitinib . In preclinical model , sorafenib inhibits KIT activity cell growth imatinib-resistant tumor . The objective multi-center , non-randomized phase II study evaluate safety activity sorafenib give third-line therapy GIST .</brief_summary>
	<brief_title>Sorafenib Imatinib/Sunitinib-failed GIST</brief_title>
	<detailed_description>This non-randomized , open-label , multi-center , phase II study recruit patient advanced GIST pretreated imatinib sunitinib . The current study provide estimate activity safety sorafenib GIST . The primary study endpoint disease control rate ( DCR ) , define complete partial response stable disease least 24 week sorafenib therapy . Secondary endpoint include PFS , OS safety . Patients advance ( unresectable and/or metastatic ) GIST fail previous therapy involve imatinib sunitinib eligible . Failure imatinib sunitinib define disease progression regardless intervene response therapy , intolerance . There limit number prior therapy patient may receive ( e.g. , patient may receive therapy nilotinib , TKIs , chemotherapy addition imatinib sunitinib ) .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>age 18 year advanced GIST fail ( progressed and/or intolerable ) prior treatment GIST ECOG performance status 0~2 resolution toxic effect prior treatment prior radiotherapy within 1 month registration measurable lesion define RECIST adequate marrow , hepatic , renal cardiac function provision sign write informed consent severe comorbid illness and/or active infection pregnant lactate woman history malignancy active CNS disease controllable radiotherapy corticosteroid active uncontrollable bleed gastrointestinal tract prior history sorafenib use gastrointestinal obstruction malabsorption syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>GIST</keyword>
	<keyword>Refractory</keyword>
	<keyword>advanced GIST fail imatinib sunitinib</keyword>
</DOC>